Electronic Health Reporter

By Neil Panchal, DO, chief medical officer, Longevitix.

A fasting insulin of nine is unremarkable on paper. So is a five. But a patient who moves from five to nine over three annual panels is telling a different story than one who has held steady at eight for a decade, even though both sit inside the same reference range that day. A reference range says whether a value is abnormal today, not where it’s headed. In midlife care, direction carries more weight than the cutoff.

That’s the shift preventive medicine needs to make, and midlife women’s health is where it shows up first. Most panels are still ordered as single events and read against a population range built for someone else’s baseline. A woman’s own prior values are the better comparator.

A 46-year-old referred for a routine cardiovascular check has an LDL-C of 118, comfortably inside range, nothing on that line asking for action. But her fasting insulin has drifted from six to 11 over three annual draws, still technically normal, and her triglycerides have climbed too. That combination, rising insulin and rising triglycerides, is exactly where LDL-C stops being trustworthy. LDL-C estimates how much cholesterol her particles carry; ApoB counts the particles themselves. In patients like her, the two often split, the particle count running ahead of the cholesterol estimate.

A 20-year cohort from the ATTICA study found that when the two disagree, cardiovascular risk follows ApoB, not LDL-C (NCBI). A single ApoB draw would show where she stands. Three draws, rising alongside her insulin, are what move her from watchful waiting to a statin conversation a year earlier than LDL-C alone would prompt.

Anti-Müllerian hormone works on the same logic, with a different clock. Two women in their mid-40s can post nearly identical single AMH values and be on very different timelines. Drawn again a year later, the number becomes a forecast rather than a snapshot. A woman whose AMH has fallen by half in that window is likely closer to menopause than her age suggests, and the conversation about bone density and cardiovascular risk should start now. A woman whose second draw barely moved has more time, and raising it early wastes a visit neither of you needed to spend. Research tracking AMH decline over time has found it improves menopause-timing prediction beyond age or a single value alone (NCBI). The trajectory, not the birthday, should set that timing.

The fix is discipline, not volume. For every marker on a midlife panel, a clinician should be able to name the decision it informs and the interval at which retesting would change that decision. Annual works for most. A monthly recheck mostly captures normal biological and assay variation, not real change; a genuine intervention earns an 8-to-12-week recheck, then the panel returns to annual. Broad, undirected hormone or sensitivity panels do the opposite of what they promise, producing more results than a clinic can act on while an ApoB of 118 sits unaddressed.

Trajectory reading has one hard requirement. Results have to live in one place, comparable across the labs and reference ranges that generated them. I described how we built toward that, including a full worked panel, here. Whatever system a clinic uses, a clinician reviewing a midlife panel should see the pattern across years, not just the flags from one draw; the decision about what to do with it stays with the physician.

Midlife medicine already has the data for this. What’s been missing is the habit of reading it as a trend instead of a test result.